GH Guardant Health Inc

Added $GH to watchlist too. Maybe tomorrow will be put on exposure day and let the market tell us if we are right or not.

$GH in a new 300 plus Life Sciences Study out today UBS team initiates coverage of GH as a top pick and $240 price target.

$GH BOOM BOOM BOOM! It just keeps getting better and better! “Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Increasing total covered Shield lives ages 45 and older to approximately 90 million, representing the vast majority of eligible patients in the U.S.”

$GH Been super slow but forming a nice VCP pocket. and wrekly super. been holding this for few weeks now.

$GH there is about 10% short interest, around 11 Million shares. Significant news at close on Friday could have been by design. We will know in the am.

$GH Fwiw, AstraZeneca will sell camizestrant as Etcamah and says it could ultimately top $5 billion in annual sales. Multiple and periodic tests for GH could be worth anywhere from 500mm to 2B based on my rough math.

$GH ““This approval represents a landmark shift in how we define disease progression and reinforces the transformative role of liquid biopsy in guiding therapy decisions earlier at a critical moment in a breast cancer patient’s treatment journey,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “The SERENA-6 paradigm opens a new frontier in how cancer is managed, with potential application across different diseases and therapies.” Approximately 37,000 women in the U.S. living with advanced HR-positive breast cancer being treated with an aromatase inhibitor could potentially benefit from this new therapeutic approach leading to better progression-free survival and outcomes.”

$GH (cough cough, Long) Darvas Box breakout this week. Wish volume was bigger, chance of a buyable pullback this week also so if you missed it you may get another opportunity

$GH Equibles has it in the filing data. Guardant Health, Inc. Chief Technology Officer Chudova Darya reported selling 7,738 GH shares on September 15, 2026, worth about $1.38 million, in a non-derivative Form 4.

$GH $167.14 bid. SELL/TAKE PROFIT on entire long position. HISTORY: DAC (dollar average cost includes partial SELLS to reduce investment cost to $11.24 EXIT $200.00 note: Originally, Legact Holding/ Major hoding took place on September 16, 2024 at $23.00. https://stocktwits.com/G101SPM/message/586148587 BRIEF: Guardant Health: TwinStrand Biosciences announces that the U.S. District Court for the District of Delaware entered final judgment in favor of the company and the University of Washington in their patent infringement suit against Guardant Health TwinStrand Biosciences announces that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health. The final judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two core patents underlying TwinStrand's Duplex Sequencing technology across 11 royalty-bearing products and services, and awards TwinStrand and UW more than $245.2 million in damages, accrued royalties and interest for infringement that occurred through May 31, 2026. The judgment upholds the jury's $83.4 million damages award for infringement through June 30, 2023, and follows the court's June 16, 2026, ruling resolving the parties' post-trial motions. The court awarded an additional $19.5 million in supplemental damages for sales between July 1, 2023, and Feb. 5, 2024, and $119.4 million in accrued royalties at a rate of 6% for sales between Feb. 5, 2024, and May 31, 2026. The court also awarded $22.9 million in pre-judgment and post-judgment interest. In determining past damages, the jury applied a 6% royalty to revenue attributed to the covered products and services, which represented approximately 90% of Guardant Health's total revenue during the relevant infringement period. Going forward, the court ordered Guardant Health to pay this 6% royalty on sales of the covered products and services adjudicated at trial from June 1, 2026, through expiration of the patents on March 15, 2033, payable quarterly. Interest also continues to accrue on the unpaid judgment.